AIM ImmunoTech Inc. (AIM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 70K 140K 210K Q3 '21: 126K Q4 '21: 134K Q1 '22: 139K Q2 '22: 146K Q3 '22: 134K Q4 '22: 140K Q1 '23: 156K Q2 '23: 168K Q3 '23: 193K Q4 '23: 202K Q1 '24: 193K Q2 '24: 201K Q3 '24: 190K Q4 '24: 170K Q1 '25: 146K Q2 '25: 121K Q3 '25: 112K Q4 '25: 88K Q1 '26: 94K Q2 '26: 95K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-45M -30M -15M 0 15M 30M 45M Q3 '21: -16.5M Q4 '21: -18.8M Q1 '22: -18.2M Q2 '22: -19.2M Q3 '22: -21.8M Q4 '22: -19.9M Q1 '23: -21.1M Q2 '23: -21.8M Q3 '23: -23.5M Q4 '23: -31.9M Q1 '24: -33.4M Q2 '24: -31.6M Q3 '24: -27.9M Q4 '24: -19.8M Q1 '25: -17.7M Q2 '25: -16.6M Q3 '25: -14.6M Q4 '25: -11.7M Q1 '26: -10.3M Q2 '26: -11.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-45M -30M -15M 0 15M 30M 45M Q3 '21: -17.2M Q4 '21: -19.1M Q1 '22: -19.4M Q2 '22: -18.3M Q3 '22: -20.9M Q4 '22: -19.4M Q1 '23: -19.3M Q2 '23: -19.3M Q3 '23: -20.8M Q4 '23: -29M Q1 '24: -31.1M Q2 '24: -28M Q3 '24: -23.9M Q4 '24: -17.3M Q1 '25: -15.2M Q2 '25: -16.2M Q3 '25: -15.8M Q4 '25: -14M Q1 '26: -13.3M Q2 '26: -14.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 350K 700K 1.1M Q4 '19: 893K Q1 '20: 866K Q2 '20: 851K Q3 '20: 825K Q4 '20: 806K Q1 '21: 839K Q2 '21: 918K Q3 '21: 871K Q4 '21: 849K Q1 '22: 689K Q2 '22: 479K Q2 '24: 58K Q3 '24: 36K Q4 '24: 31K Q1 '25: 33K Q2 '25: 35K Q3 '25: 95K Q4 '25: 128K Q1 '26: 122K Q2 '26: 117K Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-24M -16M -8M 0 8M 16M 24M Q3 '21: -11.1M Q4 '21: -14M Q1 '22: -13.7M Q2 '22: -14.3M Q3 '22: -15.8M Q4 '22: -16.1M Q1 '23: -17M Q2 '23: -16.9M Q3 '23: -17.6M Q4 '23: -21.3M Q1 '24: -22.4M Q2 '24: -23.3M Q3 '24: -20.7M Q4 '24: -14.9M Q1 '25: -12.4M Q2 '25: -11M Q3 '25: -12.9M Q4 '25: -11M Q1 '26: -11.3M Q2 '26: -14.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-21M -14M -7M 0 7M 14M 21M Q2 '13: -20.4M Q3 '13: -20.3M Q4 '13: -17.7M Q1 '14: -14.6M Q2 '14: -14M Q3 '14: -13.7M Q4 '14: -14.5M Q1 '15: -15.8M Q2 '15: -17.5M Q3 '15: -17.1M Q4 '15: -16.3M Q2 '17: -10.4M Q3 '17: -9.3M Q4 '17: -8M Q3 '19: -9.3M Q4 '19: -9.1M Q1 '20: -10.9M Q2 '20: -9.4M Q3 '20: -9.8M Q4 '20: -10.4M Q3 '13 Q2 '14 Q1 '15 Q4 '15 Q4 '17 Q1 '20 Q4 '20

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '22: 48M Q3 '22: 48.1M Q1 '23: 48.4M Q2 '23: 48.4M Q3 '23: 48.6M Q1 '24: 49.5M Q2 '24: 528.4K Q3 '24: 576.8K Q1 '25: 703.3K Q2 '25: 759.3K Q3 '25: 2.1M Q1 '26: 4.4M Q2 '26: 17.1M Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-21.00 -14.00 -7.00 0.00 7.00 14.00 21.00 Q3 '20: 2.12 Q4 '20: -0.50 Q1 '21: -0.36 Q2 '21: -0.37 Q3 '21: -0.37 Q4 '21: -0.40 Q1 '22: -0.40 Q2 '22: -0.38 Q3 '22: -0.43 Q4 '22: -0.40 Q1 '23: -0.40 Q2 '23: -0.40 Q3 '23: -0.43 Q4 '23: -0.60 Q1 '24: -0.64 Q2 '24: -3.54 Q3 '24: -9.38 Q4 '24: -19.04 Q1 '26: -3.24 Q2 '26: 0.01 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.